DUP 697
Latest Information Update: 07 Aug 1995
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb; Otsuka Pharmaceutical
- Developer Otsuka Pharmaceutical
- Class Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 07 Aug 1995 Discontinued-I for Osteoarthritis in Japan (Unknown route)
- 07 Aug 1995 Discontinued-I for Rheumatoid arthritis in Japan (Unknown route)